Imigran 20 mg nasal spray, solution
Authorisation PA1077/008/004 · GlaxoSmithKline (Ireland) Limited
- Licence holder
- GlaxoSmithKline (Ireland) Limited (all products →)
- Active substance
- Sumatriptan
- Clinical trials
- 2 clinical trials →
- Dosage form
- Nasal spray, solution
- Route of administration
- Nasal use
- ATC codes
- N02CC, N02CC01
- First authorised
- 07/07/1999
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Sumatriptan: supply and approvals
12 authorised products on the HPRA list contain Sumatriptan. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 27 years (since 7 July 1999). The HPRA list marks it as marketed in Ireland.
Other medicines with Sumatriptan in Ireland
8 other products on the HPRA list contain Sumatriptan, from 4 licence holders; 6 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Imigran 10 mg Nasal Spray, Solution | GlaxoSmithKline (Ireland) Limited | National authorisation (PA) | Marketed |
| Imigran Ftab 100 mg film-coated tablets | GlaxoSmithKline (Ireland) Limited | National authorisation (PA) | Marketed |
| Imigran Ftab 50 mg film-coated tablets | GlaxoSmithKline (Ireland) Limited | National authorisation (PA) | Marketed |
| SUMATRAN 100 mg tablets | Rowex Limited, | National authorisation (PA) | Marketed |
| SUMATRAN 50 mg tablets | Rowex Limited, | National authorisation (PA) | Marketed |
| Sumatran Relief 50mg tablets | Rowex Limited, | National authorisation (PA) | Marketed |
| Imigran 20 mg nasal spray, solution | IMED Healthcare Ltd. | Parallel import (PPA) | Not stated |
| Imigran Ftab 50 mg film-coated tablets | IMED Healthcare Ltd., | Parallel import (PPA) | Not stated |
Other substances in ATC group N02CC
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 9 other active substances share the group N02CC with this product:
Zolmitriptan (6) · ELETRIPTAN (3) · Sumatriptan succinate (3) · Lasmiditan Succinate (3) · Frovatriptan succinate monohydrate (2) · Almotriptan (1) · FROVATRIPTAN (1) · Naproxen sodium (1) · Naratriptan (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
GlaxoSmithKline (Ireland) Limited holds 95 products on the HPRA list, with 63 different active substances; 77 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.